FCCC LOGO Faculty Publications
Guo HT , Zhou TL , Jiang D , Cuconati A , Xiao GH , Block TM , Guo JT
Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-Akt signal transduction pathway
Journal of Virology. 2007 Sep;81(18) :10072-10080
PMID: ISI:000249315200045   
Back to previous list
Abstract
The phosphatidylinositol 3-kinase (PI3K)-protein kinase B (Akt) signaling pathway is one of the major oncogenic pathways and is activated in many types of human cancers, including hepatocellular carcinoma. It can also be activated by the hepatitis C virus (HCV) nonstructurall 5A (NS5A) protein. In the present study, we set out to determine the regulatory effects of this pathway on the replication of hepatitis B virus (HBV). Our results demonstrate that the expression of a constitutively active Akt1 profoundly inhibited HBV RNA transcription and consequently reduced HBV DNA replication in HepG2 cells. This suppression of HBV gene transcription was apparently mediated by the activation of mTOR, as it was abolished by the mTOR inhibitor rapamycin. Moreover, treatment of HBV-expressing HepG2.2.15 cells with inhibitors of PI3K, Akt, and mTOR increased the transcription of 3.5-kb and 2.4-kb viral RNA as well as the replication of HBV DNA. This observation implies that the basal level activation of this pathway in HepG2 cells regulated HBV replication. Consistent with previous reports showing that the HCV NS5A protein could bind to the p85 subunit of PI3K and activate the PI3K-Akt signal transduction pathway, our results showed that expression of this protein could inhibit HBV RNA transcription and reduce HBV DNA replication in HepG2 cells. Taken together, our results suggest that the activation of the PI3K-Akt pathway during liver oncogenesis may be at least partially responsible for the elimination of HBV replication from tumor cells and may also provide an explanation for the observed suppression of HBV replication by HCV coinfection.
Notes
ISI Document Delivery No.: 208JI Times Cited: 0 Cited Reference Count: 61 Cited References: ACS G, 1987, P NATL ACAD SCI USA, V84, P4641 BARNETT SF, 2005, BIOCHEM J 2, V385, P399 BECKELMITCHENER A, 1997, J VIROL, V71, P7917 BLIGHT KJ, 2002, J VIROL, V76, P13001 BOUCHARD MJ, 2001, SCIENCE, V294, P2376 BOUCHARD MJ, 2003, J VIROL, V77, P7713 BOYAULT S, 2007, HEPATOLOGY, V45, P42 CACCIOLA I, 1999, NEW ENGL J MED, V341, P22 CHEN SY, 2003, J BIOL CHEM, V278, P591 CHOU YC, 2005, J VIROL, V79, P1813 COORAY S, 2004, J GEN VIROL 5, V85, P1065 DUMOULIN FL, 2003, VIROLOGY, V305, P260 FONG TL, 1991, HEPATOLOGY, V14, P64 GANEM D, 1987, ANNU REV BIOCHEM, V56, P651 GRIPON P, 1989, J MED VIROL, V28, P193 GUO HT, 2005, J VIROL, V79, P2729 GUO JT, 2003, J VIROL, V77, P1885 HAY N, 2005, CANCER CELL, V8, P179 HE YP, 2002, J VIROL, V76, P9207 HERTOGS K, 1994, J VIROL, V68, P1516 HILD M, 1998, J VIROL, V72, P2600 HILL MM, 2002, PHARMACOL THERAPEUT, V93, P243 HIRT B, 1967, J MOL BIOL, V26, P365 IKEDA K, 2006, LEUKEMIA LYMPHOMA, V47, P155 KHARAS MG, 2005, CANCER RES, V65, P2047 LADNER SK, 1997, ANTIMICROB AGENTS CH, V41, P1715 LAWLOR MA, 2001, J CELL SCI, V114, P2903 LEE WM, 1997, NEW ENGL J MED, V337, P1733 LEE YI, 2001, J BIOL CHEM, V276, P16969 LOCARNINI S, 2005, SEMIN LIVER DIS S1, V25, P9 MANNOVA P, 2005, J VIROL, V79, P8742 MCMAHON BJ, 2005, SEMIN LIVER DIS S1, V25, P3 OROPEZA CE, 2007, VIROLOGY, V359, P371 OZER A, 1996, GASTROENTEROLOGY, V110, P1519 PASQUETTO V, 2002, J VIROL, V76, P5646 RODRIGUEZINIGO E, 2005, J VIROL, V79, P15578 SARBASSOV DD, 2006, MOL CELL, V22, P159 SCHUTTLER CG, 2002, J HEPATOL, V37, P855 SEEGER C, 2000, MICROBIOL MOL BIOL R, V64, P51 SELLS MA, 1988, J VIROL, V62, P2836 SHEEN IS, 1992, J INFECT DIS, V165, P831 SHIH CH, 1989, P NATL ACAD SCI USA, V86, P6323 SHIH CM, 1993, J VIROL, V67, P5823 SHIH CM, 1995, J VIROL, V69, P1160 STREET A, 2004, J BIOL CHEM, V279, P12232 STREET A, 2005, J VIROL, V79, P5006 SUK FM, 2002, J VIROL, V76, P12069 SUMMERS J, 1975, P NATL ACAD SCI USA, V72, P4597 SUMMERS J, 1982, CELL, V29, P403 VANNUNEN AB, 2001, LIVER, V21, P45 VOGT PK, 2006, VIROLOGY, V344, P131 WANG GH, 1992, CELL, V71, P663 WANG GH, 1993, J VIROL, V67, P6507 WANG RYL, 2005, J VIROL, V79, P13116 WU JC, 1991, J VIROL, V65, P1099 WU TT, 1990, VIROLOGY, V175, P255 XIAO GH, 2001, P NATL ACAD SCI USA, V98, P247 XU C, 2006, VIROLOGY, V359, P283 YEH CT, 1998, J MED VIROL, V55, P42 ZHENG YY, 2003, J VIROL, V77, P7707 ZHOU TL, 2006, ANTIVIR RES, V72, P116